Quantitative T1 brain mapping in early relapsing-remitting multiple sclerosis: longitudinal changes, lesion heterogeneity and disability - Takeaways - MDSpire

Quantitative T1 brain mapping in early relapsing-remitting multiple sclerosis: longitudinal changes, lesion heterogeneity and disability

  • By

  • James G. Harper

  • Elizabeth N. York

  • Rozanna Meijboom

  • Agniete Kampaite

  • Michael J. Thrippleton

  • Patrick K. A. Kearns

  • Maria del C. Valdés Hernández

  • Siddharthan Chandran

  • Adam D. Waldman

  • November 9, 2023

  • 0 min

Share

  • 1

    The study investigates T1 brain mapping to assess microstructural changes in early relapsing-remitting multiple sclerosis (RRMS).

  • 2

    Prolonged T1 components in brain tissues are hypothesized to correlate with worsening clinical disability in RRMS patients over time.

  • 3

    Seventy-nine patients with recently diagnosed RRMS were recruited for a longitudinal study assessing T1 heterogeneity and disability.

  • 4

    Quantitative T1 mapping may provide a non-invasive marker of myelin density and better predict clinical outcomes than traditional MRI assessments.

  • 5

    The study aims to explore the relationship between T1 prolongation, lesion heterogeneity, and clinical disability in early RRMS.

Original Source(s)

Quantitative T1 brain mapping in early relapsing-remitting multiple sclerosis: longitudinal changes, lesion heterogeneity and disability

  • by James G. Harper, Elizabeth N. York, Rozanna Meijboom, Agniete Kampaite, Michael J. Thrippleton, Patrick K. A. Kearns, Maria del C. Valdés Hernández, Siddharthan Chandran, Adam D. Waldman

  • November 9, 2023

Related Content

Multiple sclerosis as a biological and clinical continuum: from risk factors to the early stages of disease

Who Decides When a Doctor Steps Back?

Cognitive decline, credentialing, and why “I’ll know” often isn’t enough.

Patient Satisfaction in Relapsing-Remitting Multiple Sclerosis: Benefits of Home-Based Self-Administration of Subcutaneous Ofatumumab Compared to Other High-Efficacy Treatments